Johnson & Johnson Vision, Alcon engaged in intellectual property dispute

Article

After a US District judge rules against request for preliminary injunction, Johnson & Johnson Vision moves forward with litigation in several countries, including the United States, to resolve intellectual property disputes against Alcon.

Johnson & Johnson Vision and Alcon engaged in intellectual property dispute

Johnson & Johnson Vision (J&J Vision) is pursuing litigation in several countries, including the United States, to resolve an intellectual property dispute against Alcon, according to a prepared statement.

The lawsuit, filed in the U.S. District Court in Delaware, alleges that Alcon’s LenSx Femtosecond Laser Systems infringe on J&J Vision’s JJV's copyrighted source code as well as certain patents relating to the CATALYS Precision Laser System.

Alcon has also asserted patent infringement claims against J&J in the United States and in Europe relating to J&J’s Catalys femtosecond laser system. Both parties have asserted that the other’s patents are invalid, and both parties deny infringing the other party’s patent rights.

In February, J&J Vision filed a motion for a preliminary injunction against Alcon in its U.S. case, asking the court to prevent Alcon from selling new and refurbished LenSx femtosecond laser systems while the suit is pending.

Last week, the court ruled that a preliminary injunction was not warranted because the injuries claimed by J&J, if proven at trial, would be adequately compensated by money damages and J&J waited more than six years to file suit.

Alcon released a statement today saying the company “is confident in its position and will continue to defend its rights and prosecute its claims of patent infringement against J&J Vision in the United States and Europe.”

Alcon also was buoyed by the District Court ruling denying J&J Vision’s request for a preliminary injunction.

“For the benefit of customers and patients around the world, and consistent with that ruling, Alcon will continue to sell, install and service LenSx Laser Systems,” the statement concluded. “As a matter of corporate policy, we have no further comment on pending or ongoing litigation.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.